Has Ira Dunkel received payments from drug or device companies?

Yes. Drug and device makers reported $59,834 in general payments to Ira Dunkel across 33 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ira Dunkel did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ira Dunkel come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ira Dunkel

Pediatric Hematology-Oncology · New York, NYNPI 1003887746

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $48,763 of the $59,834 with a category attached, or 81.5%. 6 manufacturers reported payments, led by AstraZeneca at 48.6% of the total. Reporting peaked in 2020 at $16,053 and has fallen 74.4% since, to $4,110 in 2025. Among pediatric hematology-oncology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$59,834in general payments, 2019–2025

Across 33 payments — averaging $1813.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$29K
F. Hoffmann-la Roche AG$14K
Astrazeneca UK Limited$11K
GSK$4K
E.r. Squibb & Sons, L.L.C.$2K
Bristol Myers Squibb$583

$279,105in research payments, 2019–2025

Across 15 payments — averaging $18,607 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

E.r. Squibb & Sons, L.L.C.$259K
Novartis$17K
Pfizer$2K
Bristol Myers Squibb$565

What the payments were for

Consulting fees$48,76381%
Travel & lodging$10,89418%
Food & beverage$1770%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	11	$29,052
F. Hoffmann-la Roche AG	5	$13,726
Astrazeneca UK Limited	13	$10,848
GSK	1	$3,900
E.r. Squibb & Sons, L.L.C.	1	$1,725
Bristol Myers Squibb	2	$583

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

COTELLIC$13,645
Alecensa$13,645
Non-Covered Product$13,645
Truqap$7,193
KOSELUGO$4,110

How this compares

$59,834 in reported general payments places this provider in the 90th percentile of 196 pediatric hematology-oncology providers in New York.

See all pediatric hematology-oncology providers in New York →

Other pediatric hematology-oncology in New York

Sujit ShethNew York$359K
Jaap Jan BoelensNew York$303K
James BusselNew York$204K
Saara KavianyNew York$144K
Gary BrittenhamNew York$137K
James FerraraNew York$118K
John LevineNew York$98K
Nai-Kong CheungNew York$86K
Andrew HarrisNew York$85K
Joseph OvedNew York$77K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →